Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD
Status:
Terminated
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This phase II/III trial will investigate the ability of chemotherapy with 'Intensified
Aklylating Agents (IAA) to achieve a high pathological complete response (pCR) rate when
employed in the preoperative chemotherapy of breast cancer with evidence of a Homologous
Recomination Deficiency (HRD).